Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients

Table 3

Proportion of subjects with >50% reduction in non-HDL-c and LDL-c.

Variable	8 weeks			16 weeks
	n = 86 (%)	∆		n = 83 (%)	∆
Non-high-density lipoprotein cholesterol
>50%	37 (43.0)	−60.1 (−67.0; −57.4)	0.001	38 (45.8)	−62.6 (−66.8; −56.9)	0.001
<50%	49 (57.0)	−29.8 (−37.2; −5.8)		45 (54.2)	−24.5 (−38.4; 2.6)
Low-density cholesterol
>50%	46 (54.8)	−88.6 (−103.1; −67.2)	0.001	43 (53.1)	−89.3 (−11.8; −62.2)	0.001
<50%	38 (45.2)	−20.9 (−40.4; 0.0)		38 (46.9)	−7.0 (−36.3; 3.0)

; Comparison of deltas (Δ) between reduction groups (<50% vs >50%) with the Mann–Whitney U test for independent samples, ; comparison of proportions at 8 vs. 16 weeks with the McNemar’s test. For the LDL-c variable, information was obtained from 84 patients for 8 weeks follow up and 81 patients for 16 weeks follow up.